The juvenile gangliosidoses: A timeline of clinical change
Background: The gangliosidoses are rare inherited diseases that result in pathologic accumulation of gangliosides in the central nervous system and other tissues, leading to severe and progressive neurological impairment and early death in the childhood forms. No treatments are currently approved fo...
Main Authors: | Kelly E. King, Sarah Kim, Chester B. Whitley, Jeanine R. Jarnes-Utz |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426920301221 |
Similar Items
-
Chitotriosidase as a biomarker for gangliosidoses
by: Sarah Kim, et al.
Published: (2021-12-01) -
An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis
by: Esra Er, et al.
Published: (2018-03-01) -
White Matter Pathology as a Barrier to Gangliosidosis Gene Therapy
by: Anne S. Maguire, et al.
Published: (2021-08-01) -
Prenatal Diagnosis Of Tay-Sachs Disease
by: Özgür Özyüncü, et al.
Published: (2010-04-01) -
GM2 gangliosidoses: evaluation of clinical, biochemical and genetic findings of patients with three novel mutations
by: Berrak Bilginer Gürbüz, et al.
Published: (2021-09-01)